Ilary Ruscito

Scopus Publications

First-line immunotherapy with or without PARP inhibitors in advanced ovarian cancer: A meta-analysis including bevacizumab use, molecular status, and PD-L1 expression
Claudia Marchetti, Carolina Maria Sassu, Amedeo Cefaliello, Giorgia Russo, Serena Maria Boccia, Adriana Ionelia Apostol, Ilary Ruscito, Luca Romano, Christian Marth, Anna Fagotti, Francesca De Felice
Critical Reviews in Oncology Hematology, 2026
Predictive biomarkers for immunotherapy response in ovarian cancer: the role of repair assisted damage detection (RADD)
Ilary Ruscito, Giorgia Russo, Adriana Ionelia Apostol, Marica Marraffa, Amedeo Cefaliello, Serena Maria Boccia, Carolina Maria Sassu, Anna Fagotti, Claudia Marchetti
Expert Review of Clinical Pharmacology, 2026
1. During the last 15 years, the international gynecologic oncology community recognized epithelial ovarian cancer (EOC) disease as a heterogeneous group of neoplasms with different molecular chara...
The impact of BRCA status on the efficacy of paclitaxel monotherapy in recurrent ovarian cancer
Giorgia Russo, Adriana Ionelia Apostol, Ilary Ruscito, Carolina Maria Sassu, Claudia Diella, Fabiana Salvati, Filippo Maria Capomacchia, Serena Maria Boccia, Laura Vertechy, Christian Marth, Anna Fagotti, Claudia Marchetti
International Journal of Gynecological Cancer, 2026
OBJECTIVE: In BRCA-mutated (BRCAmut) patients, while sensitivity to platinum has been assessed, the efficacy of other chemotherapy drugs, such as paclitaxel, in the recurrent setting is less defined. To this purpose, a single-center retrospective study was designed to evaluate the effects of paclitaxel monotherapy in patients with platinum-resistant ovarian cancer based on BRCA status. METHODS: We collected data on patients with recurrent high-grade epithelial ovarian cancer treated with paclitaxel monotherapy between November 2017 and October 2024. Only patients who received 2 to 4 previous lines of chemotherapy before paclitaxel were selected. BRCAmut patients were compared with BRCA wild-type (BRCAwt) patients. The primary outcome was the impact of paclitaxel monotherapy on overall survival in both groups separately. The secondary outcomes were progression-free survival, response rate, and toxicity profile. RESULTS: Of 175 patients who received paclitaxel, 155 met the inclusion criteria: 50 (32.3%) BRCAmut and 105 (67.7%) BRCAwt patients. Median progression-free survival was 5 months (95% confidence interval [CI] 3.58 to 6.42) in the BRCAwt group compared with 4 months (95% CI 2.29 to 5.71) in the BRCAmut group (p = .013). In BRCAmut patients, median overall survival was 11 months (95% CI 8.28 to 13.72) compared with 18 months for the BRCAwt group (95% CI 16.04 to 19.96) (p < .001). In the 93 patients who had previously received poly (ADP-ribose) polymerase (PARP) inhibitors, overall survival remained significantly longer in BRCAwt patients (p = .004), but not progression-free survival (p > .05). CONCLUSIONS: Treatment with paclitaxel monotherapy seems to be less effective in patients with recurrent platinum-resistant BRCAmut ovarian cancer compared with the BRCAwt population. Further clinical studies are needed to confirm these data and investigate potential mechanisms of paclitaxel resistance in BRCAmut carriers.
Mesothelin in solid tumors: biology, biomarker utility, and therapeutic targeting
Ilary Ruscito, Elizaveta Baisheva, Eliane T. Taube, E. Ioana Braicu
Current Opinion in Obstetrics and Gynecology, 2025
Purpose of review Mesothelin (MSLN) is a CA125-binding surface glycoprotein that mediates cell adhesion and peritoneal metastasis development in mesothelioma, high-grade serous ovarian cancer (HGSOC), pancreatic ductal adenocarcinoma, and cholangiocarcinoma. Recent findings Because of its tumor-restricted expression and functional role in dissemination, MSLN is represents an attractive molecule to target in solid tumors. Several antibody-based therapeutic agents, vaccine and chimeric antigen receptor therapy directed against MSLN are object of clinical evaluation. MSLN-targeted therapies are limited by antigen shedding and on-target/off-target effects. Summary MSLN is expressed in solid tumor patients, with no differences in expression among histologies. MSLN expression is associated with Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) stage and platinum sensitivity. Higher MSLN expression is detected among primary ovarian cancer patients and correlates with better survival data in HGSOC patients only. According to our data, treatment strategies targeting MSLN should be offered in first line setting rather than in relapse.
Is Adenomyosis Associated with Systemic Vascular Complications?
Marwan Habiba, Ilary Ruscito, Paola Bianchi, Sun-Wei Guo, Giuseppe Benagiano
Reproductive Medicine, 2025
We carried out a comprehensive literature search for publications on the range of vascular events that have been linked to adenomyosis. This covered vascular diseases, blood coagulation disorders, thrombosis, hypercoagulation, stroke (embolic, ischemic, thrombotic, hemorrhagic), cerebrovascular episodes, cerebral infarction, cerebral hemorrhage) and renal disease. This review covers 63 articles. Nineteen articles reported clinical manifestations of intravascular thrombosis in women with adenomyosis. Eleven publications were identified that reported on cerebral involvement and adenomyosis, including cases of ischemic stroke or infarction. Dysregulation primarily seems to occur via local factors leading to altered angiogenesis. Five case reports were identified that reported on various vascular complications attributed to the presence of adenomyosis. The search also identified reports of cerebral complications in women with adenomyosis. Through a secondary search, we identified publications dealing with a possible connection between cardiac complications and renal pathology, which the authors attributed to adenomyosis. Vascular involvement in adenomyosis is documented in rare cases by the presence of endometrial tissue in myometrial vessels both in menstrual and non-menstrual uteri. Women with adenomyosis have a higher platelet count, a shorter thrombin and prothrombin time and an activated partial thromboplastin time. These findings has been applied to attempts to identify therapies for adenomyosis based on targeting the vasculature, but the existence of a link between the two conditions is under question for several reasons: only case reports (or very small series) have been published; all published cases come from one region of the world (the Far East); the published literature does not contain objective proof of a causal relationship between the two pathologies, except for the elevation of some markers. In summary, it is not possible to conclude that the presence of adenomyosis has a pathogenetic role in causing vascular events, first and foremost because available evidence consists mostly of case reports.
Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy
Adriana Ionelia Apostol, Matteo Bruno, Carolina Maria Sassu, Serena Maria Boccia, Laura Vertechy, Giorgia Russo, Ilary Ruscito, Filippo Maria Capomacchia, Giovanni Scambia, Anna Fagotti, Claudia Marchetti
International Journal of Clinical Oncology, 2025
Background Niraparib is approved for maintenance treatment of tubo-ovarian cancer patients, but data on older patients are limited. This retrospective study evaluated its safety and efficacy in primary advanced tubo-ovarian cancer, focusing on patients ≥ 75 years. Methods Women aged ≥ 50 years diagnosed with primary high-grade serous tubo-ovarian cancer, treated with niraparib between 2019–2023, were enrolled. Patients were stratified into three groups: A (50–64 years), B (65–74 years), and C (≥ 75 years). The primary outcome was progression-free survival. The secondary outcomes were toxicity and dose reduction. Results 127 patients were identified: 62 (48.8%) group A, 26 (20.5%) group B, and 39 (30.7%) group C. Baseline characteristics were comparable across groups, excluding a higher proportion of interval cytoreductive surgeries ( p = 0.001), residual tumor ( p = 0.01) and Eastern Cooperative Oncology Group (ECOG) > 1 ( p = 0.01) in group C. Most patients started niraparib at 200 mg/day with dose reductions primarily occurred within fourth cycle. Dose reductions were observed in 77.4%, 69.2% and 56.4% of patients in groups A, B, and C, respectively ( p = 0.08). In patients ≥ 75 years, 26 (66.7%) discontinued treatment due to disease progression (48.7%) or toxicity (17.9%). There were no significant differences in common or grade ≥ 3 adverse events between groups. Progression-free survival was 12 months (95%CI: 2.0–25.0) for group A, 29 months (95%CI: 11.0–52.0) for group B, and 16 months (95%CI: 1.0–31.0) for group C ( p = 0.78). Conclusions Our findings suggest that niraparib is safe and well-tolerated in aged ≥ 75 years. Concerns about toxicity should not preclude the enrollment of elderly patients in treatment regiments.
Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis
Laura Vertechy, Raffaella Ergasti, Cristina Chiamenti, Davide Arrigo, Ilary Ruscito, Alessandra Rizzi, Serena Maria Boccia, Carolina Maria Sassu, Giovanni Scambia, Anna Fagotti, Claudia Marchetti
International Journal of Clinical Oncology, 2025
Failure of early interval debulking surgery after standard neoadjuvant chemotherapy: May bevacizumab add something? A large retrospective study
Raffaella Ergasti, Laura Vertechy, Ilary Ruscito, Serena Maria Boccia, Luigi Congedo, Carolina Maria Sassu, Filippo Maria Capomacchia, Barbara Costantini, Maria Grazia Distefano, Giovanni Scambia, Anna Fagotti, Claudia Marchetti
European Journal of Surgical Oncology, 2025
The Relation between the Inner Myometrium and the Junctional Zone
Marwan Habiba, Ilary Ruscito, Paola Bianchi, Sun-Wei Guo, Giuseppe Benagiano
Gynecologic and Obstetric Investigation, 2025
Background: The nature and functions of the innermost layer of the myometrium, which is located immediately below the endometrium, coined the “junctional zone” (JZ), continue to be the subject of debate. The role and significance of the JZ have attracted little attention beyond its relation to the diagnosis of adenomyosis. Objectives: This review was conducted to update our current understanding of the role of the JZ as a specific uterine region. Methods: This is a comprehensive review of literature that was published in PubMed and MEDLINE platforms till April 2025 and that addresses the uterine JZ, excluding articles concerned with uterine adenomyosis. Outcome: It is not possible to reconcile JZ appearance on imaging with embryological or functional correlates. There are clear histological and immunohistological differences between the inner and outer myometrium, but the change is gradual with no demarcation of the transition. Whether the JZ has a different origin remains controversial because of the lack of supportive embryological evidence. There is evidence that JZ appearance on MRI is hormonally dependent, but it is not always recognizable and is often indistinct before puberty and after menopause. JZ seems to increase in thickness in the secretory and menstrual phases. Conclusion: While increased thickness is often considered a sign of adenomyosis, considerable uncertainty remains. We have not been able to identify studies that related features of the JZ per se to clinical outcomes. This supports the need for caution when interpreting the relevance of the JZ.
Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib
Ludovica Gnagni, Ilary Ruscito, Ilaria Grazia Zizzari, Marianna Nuti, Chiara Napoletano, Aurelia Rughetti
Critical Reviews in Oncology Hematology, 2024
Fibroblast Growth Factor Receptors (FGFRs) are emerging as key factors involved in tumorigenesis, tumor microenvironment remodeling and acquired resistance to targeted therapies. Pemigatinib is a Tyrosine-Kinase Inhibitor that selectively targets aberrant FGFR1, FGFR2 and FGFR3. Pemigatinib is now approved for advanced-stage cholangiocarcinoma (CCA) but data suggests that other tumor histotypes exhibit FGFR alterations, thus hypothesizing its potential efficacy in other cancer settings. The present systematic review, based on PRISMA guidelines, aims to synthetize and critically interpret the results of all available preclinical and clinical evidence regarding Pemigatinib use in cancer. In April 2024, an extensive search was performed in PubMed, MEDLINE, and Scopus databases using the keyword "Pemigatinib". Twenty-seven studies finally met all inclusion criteria. The promising results emerging from Pemigatinib preclinical and clinical studies pave the way for Pemigatinib extension to multiple solid cancer settings. • FGFRs promote tumorigenesis, microenvironment remodeling, and immune modulation. • Pemigatinib is a potent anti-FGFRs TKI now approved in advanced cholangiocarcinoma. • Many clinical trials are ongoing to assess Pemigatinib efficacy in other cancers. • This is a systematic review performed following PRISMA guidelines in April 2024. • This study summaries all preclinical and clinical results on Pemigatinib in cancer.
Introduction to Environmental Pollutants and Human Exposure
Donatella Caserta, Flavia Costanzi, Maria Paola De Marco, Aris Besharat, Ilary Ruscito
Environment Impact on Reproductive Health A Translational Approach, 2023
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
Jacek Glajzer, Dan Cacsire Castillo-Tong, Rolf Richter, Ignace Vergote, Hagen Kulbe, Adriaan Vanderstichele, Ilary Ruscito, Fabian Trillsch, Alexander Mustea, Caroline Kreuzinger, Charlie Gourley, Hani Gabra, Eliane T. Taube, Oliver Dorigo, David Horst, Carlotta Keunecke, Joanna Baum, Timothy Angelotti, Jalid Sehouli, Elena Ioana Braicu
Annals of Surgical Oncology, 2023
Brain metastases in breast cancer
Maria Luisa Gasparri, Rosa Di Micco, Arianna Siconolfi, Ammad Ahmad Farooqi, Gabrielle Di Bartolomeo, Veronica Zuber, Donatella Caserta, Filippo Bellati, Ilary Ruscito, Andrea Papadia, Oreste D. Gentilini
Unraveling the Complexities of Metastasis Transition from A Segmented View to A Conceptual Continuum, 2022
Quality of life and sexual functioning among endometrial cancer patients treated with one week adjuvant high-dose-rate vaginal brachytherapy schedule
Giuseppe Facondo, Gianluca Vullo, Vitaliana De Sanctis, Cecilia Vitiello, Luciano Nieddu, Marco Alfò, Claudia Scaringi, Francesca De Felice, Margherita Rotondi, Flavia De Giacomo, Ilary Ruscito, Maurizio Valeriani, Mattia Falchetto Osti
Journal of Contemporary Brachytherapy, 2022
Are we facing a new colposcopic practice in the HPV vaccination era? Opportunities, challenges, and new perspectives
Ankica Lukic, Rosa De Vincenzo, Andrea Ciavattini, Caterina Ricci, Roberto Senatori, Ilary Ruscito, Antonio Frega
Vaccines, 2021
Natural Cycle Results in Lower Implantation Failure than Ovarian Stimulation in Advanced-Age Poor Responders Undergoing IVF: Fertility Outcomes from 585 Patients
Maria Paola De Marco, Giulia Montanari, Ilary Ruscito, Annalise Giallonardo, Filippo Maria Ubaldi, Laura Rienzi, Flavia Costanzi, Donatella Caserta, Mauro Schimberni, Matteo Schimberni
Reproductive Sciences, 2021
Effects of endocrine-disrupting chemicals on endometrial receptivity and embryo implantation: A systematic review of 34 mouse model studies
Donatella Caserta, Flavia Costanzi, Maria Paola De Marco, Luisa Di Benedetto, Eleonora Matteucci, Chiara Assorgi, Maria Clara Pacilli, Aris Raad Besharat, Filippo Bellati, Ilary Ruscito
International Journal of Environmental Research and Public Health, 2021
Fibrin sealants and axillary lymphatic morbidity: A systematic review and meta-analysis of 23 clinical randomized trials
Maria Luisa Gasparri, Thorsten Kuehn, Ilary Ruscito, Veronica Zuber, Rosa Di Micco, Ilaria Galiano, Siobana C. Navarro Quinones, Letizia Santurro, Francesca Di Vittorio, Francesco Meani, Valerio Bassi, Nina Ditsch, Michael D. Mueller, Filippo Bellati, Donatella Caserta, Andrea Papadia, Oreste D. Gentilini
Cancers, 2021
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: A multicenter analysis
Joanna Baum, Elena Ioana Braicu, Oliver Hunsicker, Ignace Vergote, Nicole Concin, Els Van Nieuwenhuysen, Aarne Feldheiser, Patriciu Achimas-Cadariu, Silvia Darb-Esfahani, Astrid Berger, Bogdan Fetica, Sven Mahner, Andrea Papadia, Linn Wölber, Maria Luisa Gasparri, Adriaan Vanderstichele, Pierluigi Benedetti Panici, Michael D Mueller, Ilary Ruscito, Hannah Woopen, Jalid Sehouli
International Journal of Gynecological Cancer, 2021
Biological Impact of Unilateral Oophorectomy: Does the Number of Ovaries Really Matter?
Maria Luisa Gasparri, Ilary Ruscito, Elena Ioana Braicu, Jalid Sehouli, Luca Tramontano, Flavia Costanzi, Maria Paola De Marco, Michael D. Mueller, Andrea Papadia, Donatella Caserta, Filippo Bellati
Geburtshilfe Und Frauenheilkunde, 2021
The clinical and pathological profile of BRCA1 gene methylated breast cancer women: A meta-analysis
Ilary Ruscito, Maria Luisa Gasparri, Maria Paola De Marco, Flavia Costanzi, Aris Raad Besharat, Andrea Papadia, Thorsten Kuehn, Oreste Davide Gentilini, Filippo Bellati, Donatella Caserta
Cancers, 2021
Prognostic role of immunohistochemical overexpression of the p16 protein in women under the age of 35 and diagnosed with HSIL (CIN2) subjected to “cervix sparing” excision
A. Lukic, S. Rossi, A. Frega, I. Ruscito, P. Bianchi, F. Nobili, D. Caserta, A. Vecchione
European Review for Medical and Pharmacological Sciences, 2021
The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: Clinical and ultrasonographic reports
F. Costanzi, M. P. De Marco, C. Colombrino, M. Ciancia, F. Torcia, I. Ruscito, F. Bellati, A. Frega, G. Cozza, D. Caserta
European Review for Medical and Pharmacological Sciences, 2021
Adjuvant vaginal interventional radiotherapy in early-stage non-endometrioid carcinoma of corpus uteri: A systematic review
Francesca De Felice, Valentina Lancellotta, Lisa Vicenzi, Sara Costantini, Alfredo Antonacci, Valentina Cerboneschi, Daniela Cristino, Luca Tagliaferri, Annamaria Cerrotta, Andrea Vavassori, Sergio Gribaudo, Alessandro Colombo, Francesco Lucà, Raffaele Barbara, Monica Mangoni, Francesco Marampon, Daniela Musio, Filippo Bellati, Ilary Ruscito, Francesco Torcia, Vincenzo Tombolini, Mattia Osti, Vitaliana De Sanctis
Journal of Contemporary Brachytherapy, 2021
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
Roshni D Kalachand, Britta Stordal, Stephen Madden, Benjamin Chandler, Julie Cunningham, Ellen L Goode, Ilary Ruscito, Elena I Braicu, Jalid Sehouli, Atanas Ignatov, Herbert Yu, Dionyssios Katsaros, Gordon B Mills, Karen H Lu, Mark S Carey, Kirsten M Timms, Jolanta Kupryjanczyk, Iwona K Rzepecka, Agnieszka Podgorska, Jessica N McAlpine, Elizabeth M Swisher, Sarah S Bernards, Ciaran O’Riain, Sharon O’Toole, John J O’Leary, David D Bowtell, David M Thomas, Katharina Prieske, Simon A Joosse, Linn Woelber, Parvesh Chaudhry, Norman Häfner, Ingo B Runnebaum, Bryan T Hennessy
Journal of the National Cancer Institute, 2020
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials
Ilary Ruscito, Filippo Bellati, Isabelle Ray-Coquard, Mansoor Raza Mirza, Andreas du Bois, Maria Luisa Gasparri, Flavia Costanzi, Maria Paola De Marco, Marianna Nuti, Donatella Caserta, Sandro Pignata, Oliver Dorigo, Jalid Sehouli, Elena Ioana Braicu
Cancer Treatment Reviews, 2020
Low endometrial beta-catenin and cadherins expression patterns are predictive for primary infertility and recurrent pregnancy loss
Filippo Bellati, Flavia Costanzi, Maria Paola De Marco, Claudia Cippitelli, Antonella Stoppacciaro, Carlo De Angelis, Ilary Ruscito, Rocco Rago, Donatella Caserta
Gynecological Endocrinology, 2019
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium
Jun Guan, Silvia Darb-Esfahani, Rolf Richter, Eliane T. Taube, Ilary Ruscito, Sven Mahner, Linn Woelber, Katharina Prieske, Nicole Concin, Ignace Vergote, Els Van Nieuwenhuysen, Patriciu Achimas-Cadariu, Joanna Glajzer, Hannah Woopen, Mandy Stanske, Hagen Kulbe, Carsten Denkert, Jalid Sehouli, Elena Ioana Braicu
Journal of Cancer Research and Clinical Oncology, 2019
Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector T cell subsets
Chiara Napoletano, Ilary Ruscito, Filippo Bellati, Ilaria Grazia Zizzari, Hassan Rahimi, Maria Luisa Gasparri, Morena Antonilli, Pierluigi Benedetti Panici, Aurelia Rughetti, Marianna Nuti
Journal of Clinical Medicine, 2019
Tumor-derived microvesicles enhance cross-processing ability of clinical grade dendritic cells
Marco Dionisi, Claudia De Archangelis, Federico Battisti, Hassan Rahimi Koshkaki, Francesca Belleudi, Ilaria Grazia Zizzari, Ilary Ruscito, Christian Albano, Alessandra Di Filippo, Maria Rosaria Torrisi, Pierluigi Benedetti Panici, Chiara Napoletano, Marianna Nuti, Aurelia Rughetti
Frontiers in Immunology, 2018
Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
Ilary Ruscito, Dan Cacsire Castillo-Tong, Ignace Vergote, Iulia Ignat, Mandy Stanske, Adriaan Vanderstichele, Jacek Glajzer, Hagen Kulbe, Fabian Trillsch, Alexander Mustea, Caroline Kreuzinger, Pierluigi Benedetti Panici, Charlie Gourley, Hani Gabra, Marianna Nuti, Eliane T. Taube, Mirjana Kessler, Jalid Sehouli, Silvia Darb-Esfahani, Elena Ioana Braicu
British Journal of Cancer, 2018
The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis
Ilary Ruscito, Silvia Darb-Esfahani, Hagen Kulbe, Filippo Bellati, Ilaria Grazia Zizzari, Hassan Rahimi Koshkaki, Chiara Napoletano, Donatella Caserta, Aurelia Rughetti, Mirjana Kessler, Jalid Sehouli, Marianna Nuti, Elena Ioana Braicu
Gynecologic Oncology, 2018
TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway
Ilaria Grazia Zizzari, Chiara Napoletano, Andrea Botticelli, Salvatore Caponnetto, Fabio Calabrò, Alain Gelibter, Aurelia Rughetti, Ilary Ruscito, Hassan Rahimi, Ernesto Rossi, Giovanni Schinzari, Paolo Marchetti, Marianna Nuti
Cancer Immunology Research, 2018
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer
Mandy Stanske, Stephan Wienert, Dan Cacsire Castillo-Tong, Caroline Kreuzinger, Ignace Vergote, Sandrijne Lambrechts, Hani Gabra, Charlie Gourley, Ram N. Ganapathi, Ivonne Kolaschinski, Jan Budczies, Jalid Sehouli, Ilary Ruscito, Carsten Denkert, Hagen Kulbe, Wolfgang Schmitt, Korinna Jöhrens, Ioana Braicu, Silvia Darb-Esfahani
Neoplasia United States, 2018
Immunobiology of solid cancers: Cellular and molecular pathways as potential diagnostic and therapeutic targets
Ilary Ruscito, Elena Ioana Braicu, Maria Luisa Gasparri, Ilaria Grazia Zizzari
Biomed Research International, 2018
Current knowledge of miRNAs as biomarkers in breast cancer
Maria Luisa Gasparri, Zein Mersini Besharat, Aris Raad Besharat, Ilary Ruscito, Konstantinos Nirgianakis, Ammad Ahmad Farooqi, Andrea Papadia, Elisabetta Ferretti, Pierluigi Benedetti Panici, Michael David Mueller
Recent Trends in Cancer Biology Spotlight on Signaling Cascades and Micrornas Cell Signaling Pathways and Micrornas in Cancer Biology, 2018
PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?
Maria Gasparri, Erlisa Bardhi, Ilary Ruscito, Andrea Papadia, Ammad Farooqi, Claudia Marchetti, Giorgio Bogani, Irene Ceccacci, Michael Mueller, Pierluigi Benedetti Panici
Geburtshilfe Und Frauenheilkunde, 2017
Tumor-derived microvesicles modulate antigen cross-processing via reactive oxygen species-mediated alkalinization of phagosomal compartment in dendritic cells
Federico Battisti, Chiara Napoletano, Hassan Rahimi Koshkaki, Francesca Belleudi, Ilaria Grazia Zizzari, Ilary Ruscito, Sara Palchetti, Filippo Bellati, Pierluigi Benedetti Panici, Maria Rosaria Torrisi, Giulio Caracciolo, Fabio Altieri, Marianna Nuti, Aurelia Rughetti
Frontiers in Immunology, 2017
The efficacy of fibrin sealant patches in reducing the incidence of lymphatic morbidity after radical lymphadenectomy: A meta-analysis
Maria Luisa Gasparri, Ilary Ruscito, Daniele Bolla, Pierluigi Benedetti Panici, Michael D. Mueller, Andrea Papadia
International Journal of Gynecological Cancer, 2017
Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium
Ilary Ruscito, Dan Cacsire Castillo-Tong, Ignace Vergote, Iulia Ignat, Mandy Stanske, Adriaan Vanderstichele, Ram N. Ganapathi, Jacek Glajzer, Hagen Kulbe, Fabian Trillsch, Alexander Mustea, Caroline Kreuzinger, Pierluigi Benedetti Panici, Charlie Gourley, Hani Gabra, Mirjana Kessler, Jalid Sehouli, Silvia Darb-Esfahani, Elena Ioana Braicu
European Journal of Cancer, 2017
Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer
Maria Luisa Gasparri, Assunta Casorelli, Erlisa Bardhi, Aris Raad Besharat, Delia Savone, Ilary Ruscito, Ammad Ahmad Farooqi, Andrea Papadia, Michael David Mueller, Elisabetta Ferretti, Pierluigi Benedetti Panici
Tumor Biology, 2017
The Immunobiology of Cancer: From Tumor Escape to Cancer Immunoediting Towards Immunotherapy in Gynecologic Oncology
Maria Luisa Gasparri, Ilary Ruscito, Katayoun Taghavi, Ammad Ahmad Farooqi, Andrea Papadia, Chiara Focaccetti, Vincenzo Barnaba, Pierluigi Benedetti Panici, Michael D. Mueller
Molecular Oncology Underlying Mechanisms and Translational Advancements, 2017
Genetic versus epigenetic BRCA1 silencing pathways: Clinical effects in primary ovarian cancer patients: A study of the Tumor Bank Ovarian Cancer Consortium
Tingting Sun, Ilary Ruscito, Desislava Dimitrova, Radoslav Chekerov, Hagen Kulbe, Udo Baron, Véronique Blanchard, Pierluigi Benedetti Panici, Silvia Darb-Esfahani, Jalid Sehouli, Sven Olek, Elena Ioana Braicu
International Journal of Gynecological Cancer, 2017
Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer
Violante Di Donato, Michele Carlo Schiavi, Ilary Ruscito, Virginia Sibilla Visentin, Innocenza Palaia, Claudia Marchetti, Margherita Fischetti, Marco Monti, Ludovico Muzii, Pierluigi Benedetti Panici
Annals of Surgical Oncology, 2016
Beyond the beyond: First case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: Case report
Laura Salerno, Claudia Marchetti, Elisa Bevilacqua, Angela Musella, Lucia Riganelli, Ilary Ruscito, Giorgia Perniola, Ludovico Muzii, Pierluigi Benedetti Panici
Tumori, 2016
Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes—A Meta-Analysis
Ilary Ruscito, Maria Luisa Gasparri, Elena Ioana Braicu, Filippo Bellati, Luigi Raio, Jalid Sehouli, Michael D. Mueller, Pierluigi Benedetti Panici, Andrea Papadia
Annals of Surgical Oncology, 2016
Immunological and clinical impact of cancer stem cells in vulvar cancer: Role of cd133/cd24/abcg2-expressing cells
CHIARA NAPOLETANO, FILIPPO BELLATI, ILARY RUSCITO, MILENA PERNICE, ILARIA GRAZIA ZIZZARI, SALVATORE CAPONNETTO, FEDERICA TOMAO, LUIGI FRIGERIO, MARCO LIBERATI, AURELIA RUGHETTI, DONATELLA CASERTA, PIERLUIGI BENEDETTI PANICI, MARIANNA NUTI
Anticancer Research, 2016
Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium
Desislava Dimitrova, Ilary Ruscito, Sven Olek, Rolf Richter, Alexander Hellwag, Ivana Türbachova, Hannah Woopen, Udo Baron, Elena Ioana Braicu, Jalid Sehouli
Tumor Biology, 2016
Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial
MORENA ANTONILLI, HASSAN RAHIMI, VALERIA VISCONTI, CHIARA NAPOLETANO, ILARY RUSCITO, ILARIA GRAZIA ZIZZARI, SALVATORE CAPONNETTO, GIACOMO BARCHIESI, ROBERTA IADAROLA, LUCA PIERELLI, AURELIA RUGHETTI, FILIPPO BELLATI, PIERLUIGI BENEDETTI PANICI, MARIANNA NUTI
International Journal of Oncology, 2016
Cediranib in ovarian cancer: state of the art and future perspectives
Ilary Ruscito, Maria Luisa Gasparri, Claudia Marchetti, Caterina De Medici, Carlotta Bracchi, Innocenza Palaia, Sara Imboden, Michael D. Mueller, Andrea Papadia, Ludovico Muzii, Pierluigi Benedetti Panici
Tumor Biology, 2016
Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer
Maria Luisa Gasparri, Delia Savone, Raad Aris Besharat, Ammad Ahmad Farooqi, Filippo Bellati, Ilary Ruscito, Pierluigi Benedetti Panici, Andrea Papadia
Tumor Biology, 2016
Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study
Pierluigi Benedetti Panici, Innocenza Palaia, Claudia Marchetti, Ilary Ruscito, Margherita Fischetti, Angela Musella, Violante Di Donato, Giorgia Perniola, Laura Vertechy, Ludovico Muzii
Oncology Switzerland, 2015
Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)
Claudia Marchetti, Maria Luisa Gasparri, Ilary Ruscito, Innocenza Palaia, Giorgia Perniola, Angela Carrone, Ammad Ahmad Farooqi, Francesco Pecorini, Ludovico Muzii, Pierluigi Benedetti Panici
Critical Reviews in Oncology Hematology, 2015
PARP inhibition: A promising therapeutic target in ovarian cancer
Angela Musella, Cláudia Marchetti, Maria Luisa Gasparri, Laura Salerno, Assunta Casorelli, et al.
Cellular and Molecular Biology, 2015
Effects of unilateral ovariectomy on female fertility outcome
Filippo Bellati, Ilary Ruscito, Maria Luisa Gasparri, Morena Antonilli, Milena Pernice, Cristina Vallone, Giuseppina Morano, Piero Chirletti, Pasquale B. Berloco, Pierluigi Benedetti Panici
Archives of Gynecology and Obstetrics, 2014
Dualistic classification of epithelial ovarian cancer: Surgical and survival outcomes in a large retrospective series
Pierluigi Benedetti Panici, Claudia Marchetti, Laura Salerno, Angela Musella, Laura Vertechy, Innocenza Palaia, Giorgia Perniola, Ilary Ruscito, Terenzio Boni, Roberto Angioli, Ludovico Muzii
Annals of Surgical Oncology, 2014
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
I. Ruscito, D. Dimitrova, I. Vasconcelos, K. Gellhaus, T. Schwachula, F. Bellati, R. Zeillinger, P. Benedetti-Panici, I. Vergote, S. Mahner, D. Cacsire-Tong, N. Concin, S. Darb-Esfahani, S. Lambrechts, J. Sehouli, S. Olek, E.I. Braicu
European Journal of Cancer, 2014
Monoclonal antibodies therapies for ovarian cancer
Umberto Leone Roberti Maggiore, Filippo Bellati, Ilary Ruscito, Maria Luisa Gasparri, Franco Alessandri, Pier Luigi Venturini, Simone Ferrero
Expert Opinion on Biological Therapy, 2013
Past, present and future strategies of immunotherapy in gynecological malignancies
F. Bellati, C. Napoletano, I. Ruscito, V. Visconti, M. Antonilli, M.L. Gasparri, I.G. Zizzari, H. Rahimi, I. Palaia, A. Rughetti, P. Benedetti Panici, M. Nuti
Current Molecular Medicine, 2013
Minimal invasive approaches for large ovarian cysts: A careful choice
Filippo Bellati, Maria Luisa Gasparri, Ilary Ruscito, Jlenia Caccetta, Pierluigi Benedetti Panici
Archives of Gynecology and Obstetrics, 2013
Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms
Filippo Bellati, Chiara Napoletano, Maria Luisa Gasparri, Ilary Ruscito, Claudia Marchetti, Sandro Pignata, Federica Tomao, Pierluigi Benedetti Panici, Marianna Nuti
Critical Reviews in Oncology Hematology, 2012
Monoclonal antibodies in gynecological cancer: A critical point of view
Filippo Bellati, Chiara Napoletano, Maria Luisa Gasparri, Valeria Visconti, Ilaria Grazia Zizzari, Ilary Ruscito, Jlenia Caccetta, Aurelia Rughetti, Pierluigi Benedetti-Panici, Marianna Nuti
Clinical and Developmental Immunology, 2011
Immune effects of Trastuzumab
Marianna Nuti, Filippo Bellati, Valeria Visconti, Chiara Napoletano, Lavinia Domenici, Jlenia Caccetta, Ilaria Grazia Zizzari, Ilary Ruscito, Hassan Rahimi, Pierluigi Benedetti-Panici, Aurelia Rughetti
Journal of Cancer, 2011
Vaginal reconstruction with the Abbè-McIndoe technique: From dermal grafts to autologous in vitro cultured vaginal tissue transplant
Pierluigi Panici, Ilary Ruscito, Maria Gasparri, Diana Maffucci, Cinzia Marchese, Filippo Bellati
Seminars in Reproductive Medicine, 2011
Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
Filippo Bellati, Chiara Napoletano, Ilary Ruscito, Maria Pastore, Milena Pernice, Morena Antonilli, Marianna Nuti, Pierluigi Benedetti Panici
Investigational New Drugs, 2010
Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy
Filippo Bellati, Chiara Napoletano, Ilary Ruscito, Marco Liberati, Pierluigi Benedetti Panici, Marianna Nuti
Journal of Clinical Oncology, 2010

Ilary Ruscito

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications